sefulness and safety of Mw vaccine versus Mantoux antigen in patients of warts caused by virus
Not Applicable
- Conditions
- Health Condition 1: null- Multiple viral warts
- Registration Number
- CTRI/2017/08/009327
- Lead Sponsor
- Medical College Kolkata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
i.Male or female patients between 18 and 65 years of age (both inclusive).
ii.Multiple viral warts >=5.
iii.Patients who give their informed consent
Exclusion Criteria
i.Pregnant and lactating women.
ii.Any evidence of immunosuppression (eg. HIV infection, organ transplantation, long term steroid use etc.).
iii.Any other systemic disease (eg. liver or kidney disorder).
iv.Presence of mucosal wart(s).
v.Presence of ulcerated or inflamed wart(s).
vi.Patients who participated in a clinical trial in the last three months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of wartsTimepoint: Baseline, 2, 4, 6, 8, 10, 14, 18, 22 weeks
- Secondary Outcome Measures
Name Time Method Serum for Liver Function Test, urea, creatinine, Hemoglobin, Total count, Differential Count, Erythrocyte Sedimentation RateTimepoint: Screening visit, 10 weeks